Clinicopathology and treatment of a giant malignant phyllodes tumor of the breast: A case report and literature review

Wayne A. Warner a,b, Vandana Devika Sookdeo c,a, Maurice Fortuné d, Meenakshi Ahkilesh e, Chalapathi Rao Adidam Venkata f, Wayne Mohammed c, Cassandra Ramkissoon c, Dave Harnanan c, Lemuel Pran c, Ravi Maharaj c

a Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA
b Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA
c Department of Clinical Surgical Sciences, University of the West Indies, Eric Williams Medical Sciences Complex, Champ Fleurs, Trinidad and Tobago
d Department of Radiology, University of the West Indies, Eric Williams Medical Sciences Complex, Champ Fleurs, Trinidad and Tobago
e Department of Paraclinical Science, University of the West Indies, Eric Williams Medical Sciences Complex, Champ Fleurs, Trinidad and Tobago

A R T I C L E   I N F O
Article history:
Received 26 August 2017
Accepted 18 September 2017
Available online 4 October 2017

Keywords:
Malignant phyllodes tumor
Trinidad and Tobago
Cancer

A B S T R A C T

INTRODUCTION: Phyllodes tumors (PTs) of the breast are extremely rare accounting for less than 1% of all breast tumors globally. Case records at the Trinidad and Tobago Cancer Registry show that only 0.003% of the reported breast cancer cases between 1995 and 2009 were PTs.

PRESENTATION OF THE CASE: We report a 45-year-old woman who presented with swelling of the left breast. Ultrasound, mammogram and computed tomography imaging confirmed the presence of a mass in the right upper inner quadrant of the left breast. A biopsy revealed features supportive of a benign phyllodes tumor. A wide local excision was performed with the removal of a 19 × 11 × 10 cm mass. Histopathological analysis revealed features consistent with malignant phyllodes tumor. A complete mastectomy of the left breast was subsequently performed. Follow up over a 5-year period did not reveal any evidence of local recurrence or residual disease. To the best of our knowledge, this is the first case report of a malignant PT from the Caribbean and Latin America.

DISCUSSION: Phyllodes tumors are classified as benign, borderline, or malignant based on histologic features including presence of a clear cell, cellularity, stromal overgrowth, tumor necrosis and mitotic index. The clinical challenge is to assess the risk of local tumor and metastatic recurrence in the context of fluid classifications.

CONCLUSION: Our case management approach shows that for patients with malignant PT, a thorough preoperative workup regimen followed by appropriate surgical intervention can result in a desirable prognosis.

© 2017 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Phyllodes tumors (PTs) of the breast are circumscribed biphasic fibroepithelial neoplasms analogous to fibroadenomas [1]. PTs are characterized by a double layered epithelial component surrounded by a hypercellular mesenchymal component, typically presenting in leaf-like processes [1]. These tumors are extremely rare, globally accounting for 0.3% to 1% of all breast tumors and 2.5% of all fibroepithelial tumors of the breast [2]. They commonly occur in women 35–55 years (median 45 years) [1].

The World Health Organization (WHO) classification schema grades PTs as benign, borderline, or malignant based on stromal patterns of cellularity, nuclear atypia, mitotic activity, heterologous stromal differentiation, stromal hypercellularity, cellular pleomorphism and tumor margin appearance [1]. However, absent clear defining boundaries for each of these histologic parameters, reliable classification assignment is challenging [3].

The majority (up to 60%) of PTs are benign [1]. Distant metastases have been reported in up to 22% of malignant PTs with expansion to nearly all internal organs, in particular the lung and skeleton [3]. Axillary lymph node metastases are rare. Wide local excision or mastectomy with appropriate margins is the preferred clinical intervention [4].

https://doi.org/10.1016/j.jscr.2017.09.021
2210-2612/© 2017 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
We describe the case of a 45-year-old woman who presented to the Eric Williams Medical Sciences Complex (EWMSC), Champ Fleurs, Trinidad and Tobago (TT) with swelling of her left breast, which was later confirmed histologically to be a malignant phyllodes tumor. This case report was prepared according to the Surgical Case Report (SCARE) guidelines which provides a framework for accuracy in surgical case reports [5,6].

2. Case presentation

A 45-year-old woman of Trinidad and Tobago nationality and East Indian ancestry, presented to the emergency room of the Eric Williams Medical Sciences Complex (EWMSC) with a 3-week history of left breast swelling. She had a body mass index (BMI) of 31.8 kg/m², and reported a history of diabetes mellitus type 2 and hypertension. The patient also reported abstention from smoking and alcohol. She had four children, with the first birth occurring at 26 years.

She reported that the swelling occurred a few days after being accidentally hit on the left breast. Examination revealed a hard, nodular 13 × 10 cm mass, with no palpable axillary lymph nodes. An ultrasound revealed a heterogeneous, mostly hypoechoic mass with internal vascularity (Fig. 1A, and B). A mammogram revealed a heterogeneously dense breast tissue with a well-defined spherical opacity in the right upper inner quadrant (Fig. 2A). Further, a large mass with lobulated margins replacing most of the left breast parenchyma along with a few scattered foci of coarse, punctate and plaque-like calcifications were noted (Fig. 2B). These observations supported a clinical suspicion of phyllodes tumor. Computed tomography (CT) imaging of the chest revealed a large lobulated soft tissue density mass in the left breast (Fig. 3A–C).

An ultrasound-guided Tru-cut needle biopsy demonstrated features such as high stromal cellularity with moderate pleomorphism that would support a differential diagnosis of benign PT (Fig. 4). Histopathological examination revealed that the needle core sections were composed of cellular-stromal spindle cell lesions with hypocellular areas. The spindle cells showed mild pleomorphism, with few mitosis <5/10 high power field (hpf) and the tumor was devoid of glandular elements or foci of necrosis. However, because of heterogeneity of the tumor, wider sampling was considered essential for comprehensive evaluation.

A few weeks later, the patient returned to the hospital complaining of acute pain around the swelling. After counseling by the case management team, the patient agreed to have the mass surgically removed by wide excision. In brief, the patient was sterile prepped, draped and an elliptical incision was made around the affected area leaving 1 cm margins past the involved skin. Hemostasis was achieved using diathermy coagulation after the excision and a silicone drain was placed in situ. Her estimated blood loss was 150 ml. The deep tissues and skin were sutured with 2.0 vicryl and 3.0 prolene (subcuticular stitch looped in the middle), respectively. The operation was uneventful culminating with the excision of the large mass which was invading the skin and superior areolar complex. Postoperatively, the patient received divon (Diclofenac),
Invanz, Flagyl, an analgesic, and anti-embolism stocking. Ambulation was encouraged.

A complete mastectomy of the left breast was performed a few weeks later. In brief, the patient was sterile prepped, draped and Zinacef administered on induction. An incision made along the elliptical line drawn from the clavicle to the 6th rib to the sternum to the axillary tail. The breast was removed with deep margins including pectoralis fascia. Hemostasis was achieved and suturing was as for the prior surgery. Two silicone drains were placed in situ. Postoperatively, the patient received divon, Rocephin, an analgesic, and anti-embolism stocking. As before, ambulation was encouraged.

The excised specimen consisted of a large, firm oval mass partly covered by an ellipse of skin, measuring 20 × 15 × 10 cm. Cut sections revealed a fleshy grey-white tumor measuring 19 × 11 × 10 cm with satellite nodules close to the inferior margin. Histopathological investigations revealed that sections showed marked stromal cellularity with mild pleomorphism. Additionally, a well circumscribed cellular stromal tumor containing occasional glandular elements was observed. The epithelial component in the adjoining tissue and tumor showed ductal and lobular hyperplasia and focal in situ carcinoma (Fig. 5). There were foci of tumor necrosis, mild-moderate atypia foci of marked cellularity resembling fibrosarcoma with a mitotic index >5/10 hpf in the active areas (Fig. 6). No evidence of lympho-vascular invasions was observed. The tumor showed a predominately pushing growth pattern (Fig. 7). The medial, superior, and inferior margins were not clear. However, the posterior margin was clear but showed a breach in the capsule, while the lateral and anterior margins were close (<3 mm) but clear. These histologic features are consistent with the WHO grading for a malignant phyllodes tumor. Sections from the mastectomy specimen showed granulomatous inflammatory changes. Residual tumor was not observed in the lesion and all margins were clear.

At her bimonthly follow up appointment, Tramacet was prescribed to alleviate the intermittent pain around the incision site. She had an uneventful postoperative course and ten months later a surveillance CT did not reveal any recurrent or residual mass (Fig. 8).
After a three-year absence, the patient returned to the clinic and a surveillance abdomen/pelvis and chest CT imaging regimen did not reveal any evidence of local recurrence or residual disease. A technetium 99m (99mTc) hydroxyethylene diphosphonate (HDP) bone scan with anterior and posterior imaging was negative for uptake in the lumbar vertebral region which would have been suggestive of metastatic deposits. Stable disease with stable sclerotic lesions were observed in her lumbar vertebral bodies.

An exhaustive PubMed/Medline and EMBASE medical database search from inception (1946) to present was performed. The search strategy was created using indexing terms/keywords and the AND Boolean operator. For example; in PubMed: (Caribbean OR Latin America OR developing countries) AND (phylloides tumor OR cystosarcoma phylloides). After limiting final retrieval to English language; humans and case reports; we retrieved one citation for a benign PT [7]. To the best of our knowledge; ours is the first case report of a malignant PT in the Caribbean and Latin America. A search of the TT Cancer Registry records revealed that only 12 (0.003%) of the 4685 reported breast cancer cases between 1995 and 2009 were phylloides tumors (Table 1). All of the cases were malignant with most patients (11/12; 1 unknown) receiving only surgical intervention. The mean age at presentation was 49.

3. Discussion

In this case, there was a high degree of suspicion for a benign PT based in part, on the biopsy findings of few mitoses. However, histopathological examination of the mass revealed that the mitoses in active areas were >5/10hpf and thus strongly suggestive of malignant PT. Extensive imaging and histopathological workup is critical when a diagnosis of PT is suspected [8]. If the mass has a smooth contours, intramural cysts and low echogenicity on ultrasound, a PT is usually suspected and a core needle biopsy recommended [9,10]. In such cases, cytology specimens should contain both epithelial and stromal elements to confirm the PT diagnosis. However, there is oftentimes discordance between the core biology pathology and surgical histopathology in rendering a differential diagnosis between the various classifications of PT and fibroadenoma due to tumor heterogeneity [11,12].

All of the cases reported to the TT Cancer Registry since 1995 were classified as malignant. This is striking given that globally most PTs are benign. Distinguishing between benign, borderline, and malignant PT is critical to the development of an effective clinical management plan. There is significant variability in the interpretation of the criteria for each designation. Additionally, tumor heterogeneity, sampling errors increase reported variabilities. In fact, studies in which different pathologists have analyzed the same histological slides were marked by a 25% discordance in the final histopathological finding [13]. One approach to better delineate between benign and a malignant PT might be to assess the immunohistochemical (IHC) expression of CD10 in the stromal cells. CD10 immunoreactivity has the potential to inform on the histopathological grading of PTs, given that CD10 expression strongly correlates with PT grade [14,15]. Restaging with 18F-fluorodeoxyglucose positron emission tomography computed tomography (FDG PET-CT) could also be helpful in distinguishing between a benign and malignant PT [8]. This hybrid imaging modality benefits from the sensitivity of the PET component and the specificity of the CT component. However, it is not available in the Caribbean or most low resource countries. The challenges
of expanding nuclear medicine capacity in low resource countries were reviewed elsewhere [16,17]. The addition of FDG PET-CT to the diagnostic arsenal might be of value in developing countries given the increasing cancer burden.

While the molecular basis of phyllodes tumors largely remains unknown, the most frequent genomic insults are mutations in exon 2 of MED12, a subunit of the transcriptional mediator complex and RARA [18–20]. Interestingly, fibroadenomas also share this genetic signature [18–20]. Less frequently, mutations in FLNA, SETD2 and KMT2D have also been reported in PT. Loss of function mutations in p53, deleterious mutations in RB1 and NFI, mutations in PIK3CA and ERBB4, and high-level copy number variations of EGFR were detected in borderline and malignant tumors [20]. However, EGFR and IGF1R gene amplifications were only detected in malignant tumors [21,22]. These mutational signatures of PT provide a possible framework to distinguish between the three subtypes. This type of genome forward clinical assessment is not available in Trinidad and Tobago and the Caribbean region, in general. Capacity building towards this level of precision medicine is fiscally challenging for the region, but is crucial for long term sustainable improvements in health care [23].

Breast-conserving surgery with appropriate margins (≥ 1 cm) is the preferred primary therapy for PT in the absence of metastatic disease [4]. In this case, given the histologic confirmation of a malignant tumor, we elected to perform a wide excision in accordance with National Comprehensive Cancer Network guidelines [24] followed by a mastectomy. Axillary dissection was not performed since nodal metastases secondary to PT are very rare. The utility of adjuvant therapy in the management of PT cases is unclear and there are no prospective or randomized studies of adjuvant chemotherapy in this setting. Recent reports recommended adjuvant therapy intervention for borderline cases with maximal diameter greater than 5 cm and those with histologic evidence of stromal overgrowth, since these seem to have higher metastatic potential [4,25]. For metastatic PTs, some studies have reported promising results with administration of ifosfamide, doxorubicin and dacarbazine [26,27].

Given the absence of metastasis or recurrence in the chest wall post mastectomy, radiotherapy was not offered to this patient. In fact, there are no prospective randomized data in support of radiotherapy for PT [24]. Recent studies advocate the use of radiotherapy for borderline and malignant PT, recurrent tumors and in cases where it is not possible to achieve a greater than one-centimeter surgical margin [25,28]. Given the rarity of PT, it might be challenging to derive a randomized controlled trial with adequate sample size.

### 4. Conclusion

Phyllodes tumors are extremely rare. The major challenge facing clinicians in developing countries is the availability of clinical resources to adequately distinguish between fibroadenoma and PT, and where PT is affirmed, to arrive at the appropriate PT classification. Our experience with this case in TT shows that adequate preoperative workup followed by surgical intervention can result in an improved prognosis for patients with malignant PT.

### Conflicts of interest

None to declare.

### Funding

WAW was supported by Washington University School of Medicine, GSAS/CGFP Fund 94028C. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the views of the affiliating institutions.

### Ethical approval

Ethical approval was not required since patient is de-identified.

### Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

### Author contribution

All of the authors contributed substantially to the overall study concept, data collection, data analysis or interpretation, and writing the paper.

### Guarantor

Wayne A. Warner, Vandana Devika Sookdeo, Maurice Fortune, Meenakshi Akhilesh, Chalapathi Rao Adidam Venkata, Wayne Mohammed, Cassandra Ramkissoon, Dave Harnanan, Lemuel Pran and Ravi Maharaj.
Acknowledgements

WAW was supported by Washington University School of Medicine--St. Louis (Grant #GSAS/CGFP Fund 94028C). The authors wish to acknowledge the assistance of Kim Lipsey, Bernard Becker Medical Library, Washington University School of Medicine, St. Louis, MO, USA and Majorie Lamont-Greene, Trinidad and Tobago Cancer Registry, Mt. Hope, Trinidad and Tobago. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the views of the affiliated institutions.

References

[1] IARC, World Health Organzation Classification of Tumours of the Breast, in: S. Lakhani, et al. (Eds.), World Health Organization Classification of Tumours, vol. 4, IARC, Lyon, France, 2012.

[2] L. Bernstein, D. Deapen, R.K. Ross, The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast, Cancer 71 (10) (1993) 3020–3024.

[3] Y. Zhang, C.G. Kleer, Phyllodes tumor of the breast: histopathologic features, differential diagnosis, and molecular/genetic updates, Arch. Pathol. Lab. Med. 140 (7) (2016) 665–671.

[4] A.W. Chaney, et al., Primary treatment of cystosarcoma phyllodes of the breast, Cancer 89 (7) (2000) 1502–1511.

[5] R.A. Agha, et al., The SCARE statement: consensus-based surgical case report guidelines, Int. J. Surg. 34 (2016) 180–186.

[6] R.A. Agha, et al., A protocol for the development of reporting criteria for surgical case reports: the SCARE statement, Int. J. Surg. 27 (2016) 187–189.

[7] S. Islam, et al., The largest and neglected giant phyllodes tumor of the breast – a case report and literature review, Int. J. Surg. Case Rep. 26 (2016) 96–100.

[8] J. Chung, et al., Giant phyllodes tumors of the breast: imaging findings with clinicopathological correlation in 14 cases, Clin. Imaging 35 (2) (2011) 102–107.

[9] W. Buchberger, et al., Phyllodes tumor: findings on mammography, sonography, and aspiration cytology in 10 cases, AJR Am. J. Roentgenol. 157 (4) (1991) 715–719.

[10] H.C. Umpleby, et al., An evaluation of the preoperative diagnosis and management of cystosarcoma phyllodes, Ann. R. Coll. Surg. Engl. 71 (5) (1989) 285–288.

[11] W.H. Chen, et al., Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases, J. Surg. Oncol. 91 (3) (2005) 185–194.

[12] I.K. Komenaka, et al., Core needle biopsy as a diagnostic tool to differentiate phyllodes tumor from fibroadenoma, Arch. Surg. 138 (9) (2003) 987–990.

[13] S.J. Parker, S.A. Harries, Phyllodes tumours, Postgrad. Med. J. 77 (909) (2001) 428–435.

[14] M.M. Kulkarni, et al., Role of CD10 immunoeexpression in grading phyllodes tumour of the Breast, J. Clin. Diagn. Res. 11 (1) (2017) E14–E16.

[15] V. Puri, et al., Critical appraisal of stromal CD10 staining in fibroepithelial lesions of breast with a special emphasis on expression patterns and correlation with WHO grading, J. Cancer Res. Ther. 12 (2) (2016) 667–670.

[16] D. Paez, et al., Current status of nuclear medicine practice in Latin America and the Caribbean, J. Nucl. Med. 56 (10) (2015) 1629–1634.

[17] M. Dondi, et al., Trends in nuclear medicine in developing countries, J Nucl Med 52 (Suppl. 2) (2011) 16s–23s.

[18] M. Yoshida, et al., Frequent MED12 mutations in phyllodes tumours of the breast, Br. J. Cancer 112 (10) (2015) 1703–1708.

[19] S. Nagasawa, et al., MED12 exon 2 mutations in phyllodes tumours of the breast, Cancer Med. 4 (7) (2015) 1117–1121.

[20] J. Tan, et al., Genomic landscapes of breast fibroepithelial tumors, Nat. Genet. 47 (11) (2015) 1341–1345.

[21] A.K. Cani, et al., Next-Gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors, Mol. Cancer Res. 13 (4) (2015) 613–619.

[22] C. Kersting, et al., Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression, Lab. Invest. 86 (1) (2006) 54–61.

[23] A. Roach, W.A. Warner, A.A.M. Llanos, Building capacity for human genetics and genomics research in Trinidad and Tobago, Revista panamericana de salud publica = Pan Am. J. Public Health 38 (5) (2015) 425–430.

[24] National Comprehensive Cancer Network, NCCN Guidelines Version 2.2017 Phyllodes Tumor, 2017 [cited 2017 April 2017]; Available from: https://www.nccn.orgprofessionals/physician-gl/pdf/breast.pdf.

[25] C.A. Ossa, et al., Phyllodes tumor of the breast: a clinic-pathologic study of 77 cases in a Hispanic cohort, Colomb. Med. (Cali.) 46 (3) (2015) 104–108.

[26] R.E. Hawkins, et al., Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes, Cancer 69 (9) (1992) 2271–2275.

[27] F. Morales-Vazquez, et al., Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast, Breast J. 13 (6) (2007) 551–556.

[28] Y. Belkacemi, et al., Phyllodes tumor of the breast, Int. J. Radiat. Oncol. Biol. Phys. 70 (2) (2008) 492–500.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the JJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.